about
Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular diseaseRomosozumab Treatment in Postmenopausal Women with OsteoporosisImpact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing ratsMicrodialysis Sampling from Wound Fluids Enables Quantitative Assessment of Cytokines, Proteins, and Metabolites Reveals Bone Defect-Specific Molecular ProfilesOrchiectomy upregulates free soluble RANKL in bone marrow of aged ratsSkeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes.More DATA to guide sequential osteoporosis therapy.[Rheumatoid arthritis, neutropenia and splenomegaly: the Felty syndrome]Artificial extracellular matrices with oversulfated glycosaminoglycan derivatives promote the differentiation of osteoblast-precursor cells and premature osteoblastsThe roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases.Bone and mineral metabolism in human immunodeficiency virus infection.Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts.Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cellsRANK ligand and osteoprotegerin in myeloma bone disease.Myelodysplasia is in the niche: novel concepts and emerging therapies.Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients.Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid.Cancer-targeted therapies and radiopharmaceuticalsClinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone DiseaseAssociations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children.Regulation of VEGF by mevalonate pathway inhibition in breast cancerZoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cellsFatal attraction: why breast cancer cells home to bone.Osteoporosis in patients with diabetes mellitus.Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.Minireview: live and let die: molecular effects of glucocorticoids on bone cells.Medial arterial calcification in diabetes and its relationship to neuropathy.Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.Approach to the patient with secondary osteoporosis.The role of osteoclast-associated receptor in osteoimmunology.Denosumab for bone diseases: translating bone biology into targeted therapy.Regenerative potential of glycosaminoglycans for skin and bone.Bone, sweet bone--osteoporotic fractures in diabetes mellitus.The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.Novel therapies in benign and malignant bone diseases.Skeletal and extraskeletal actions of denosumab.
P50
Q28206678-15375043-A7A3-4E17-A96E-049701E90251Q28278665-82C5BC05-759F-4D10-90E2-C9F81DC5E9D9Q28548625-D63B62DC-D8D4-4EE5-90CD-4250598D75DBQ28552772-47CB0564-210C-4D54-AB10-4C7714B737E4Q28568938-FBC9F733-9951-4D3D-B4E3-E20428BA626BQ30249436-5E3D9627-E2C4-4429-83A8-3084C8BF3761Q30978612-1AAB2D58-9592-4229-8FCA-7EB9DD426A82Q33487670-3AF1D5CA-B5C9-4617-9D8B-7A8709D0A5B3Q33609014-BA8384F5-58A6-446E-9832-8145C6FF5741Q33823576-1BA0448B-996F-4A21-95C5-FFBDE0BC572DQ33973495-3D47463B-9375-4EB3-9FF7-FB11D10A81FEQ34125502-A187A6B1-B860-4EFE-859C-6FE682F532ABQ34383078-CF8FB187-0CC9-42F7-8374-C893E5FBFE4FQ34967135-0FC14661-F624-48F7-BA32-0D7D979275D5Q34992857-0C635B08-93AA-4335-B115-2F112F5774E8Q35059425-74970730-CC1D-4A24-95AC-2DD3B956836CQ35087364-C48B3153-536A-4A16-A21D-038130FCC9DDQ35237099-C73E256F-0D89-4B5C-A3B6-BF0F27A9EA6FQ35309369-C774A0F0-AEBB-419A-822B-4606D628022EQ35683440-D9E0F8A0-1D8A-4A79-B287-2C7CD1A325DDQ35848843-E98806DC-4897-4383-B664-E3BE19A33F27Q36011988-93811F87-71F0-44DF-809B-B40AAB511B69Q36370950-E7F322B0-05F6-4FEF-8B6D-C98E66B87492Q36491540-9B6B74F9-1CB7-4EB6-8B46-F915AB9C742CQ36491662-5485D768-20AF-47CC-BAC3-314878BDA797Q36643034-6FF0B370-8C5D-4517-9768-7B1A2BF2C6DBQ36821345-5321357D-B1E4-4ADD-B509-FB294BC414FFQ37278407-5ebaa173-4cc3-335b-c099-febff513c364Q37298020-F86E1A81-4616-4D35-B89D-4056AB129AC1Q37499649-E88454B5-D292-410B-A524-3CD4566328DCQ37597984-F9AE354A-3AC2-4170-8401-E7C272E71E78Q37690947-DE21F38B-C41A-4C09-B3A8-8C9D8190F3B9Q37709743-A33B49A4-F4F1-4BEB-86CC-E5975D55833EQ37822578-EE60CB94-CBD5-4E87-AC11-2D18B06F3395Q37919678-280F2D7B-4B8A-4684-9B56-7CF6CDA6A9F6Q37970313-F05850B8-CA76-4E99-8ABB-81A2CFE50E5EQ37976305-096115C2-B7EE-4D81-A3F3-A4F0345CF4B2Q37980961-667087A3-CFD4-4A2E-B41D-42D24B98B4B4Q37991789-347E9765-1DF2-4DE8-9633-FDC3EE7FCE75Q38009712-CB331EB5-B72C-4179-9EDB-15E009DF3AF4
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lorenz C Hofbauer
@ast
Lorenz C Hofbauer
@en
Lorenz C Hofbauer
@es
Lorenz C Hofbauer
@nl
type
label
Lorenz C Hofbauer
@ast
Lorenz C Hofbauer
@en
Lorenz C Hofbauer
@es
Lorenz C Hofbauer
@nl
altLabel
Lorenz C. Hofbauer
@en
prefLabel
Lorenz C Hofbauer
@ast
Lorenz C Hofbauer
@en
Lorenz C Hofbauer
@es
Lorenz C Hofbauer
@nl
P1053
G-2490-2010
P106
P21
P31
P496
0000-0002-8691-8423